A double-blind, placebo controlled multicentre study to evaluate the e
A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.
What was tested
Treatment tested
- Dirucotide
What it measured
Main measures
The primary endpoint is a statistically and clinically significant increase in the time to confirmed worsening of disability as measured by EDSS.
Disability progression
Loading reviews and guidelines…
Related trials
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cel
Phase 1 / Phase 2 · Not yet recruiting
Still running
- A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) fo
Phase 2 · Not yet recruiting
Still running
- Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis
Phase 2 · Not yet recruiting
Still running
- Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Phase 1 · Recruiting
Still running
- Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Tre
Phase 1 · Recruiting
Still running
- Nasal Foralumab in Patients With Non-Active Secondary Progressive Mult
Phase 2 · Recruiting
Still running
History
- In scope changed from true to false
Started
Feb 2005
Assembled by software from public sources.